The global medical device market is undergoing profound changes with the rise of China, particularly in the mid-to-low-risk medical devices and consumables sectors, where China’s market share and importance are steadily increasing. This growth is not only due to heightened health awareness post-pandemic, the expansion of the middle class, an aging population, and the push from national healthcare policies but also reflects the increasing preference of Chinese consumers for domestic brands. GaleMed, a global company with 37 years of expertise in respiratory care, has keenly recognized these market changes and established its new factory, Aplus, in Xiamen, China, in 2024.

Sunny He, Sales Director of Aplus (Xiamen) Medical Supply Co., Ltd., stated that in the face of tremendous competitive pressure, companies are competing not only in terms of speed and price but also in product quality and innovation capabilities. The Aplus factory not only enhances GaleMed's production and service capabilities in the Chinese market but also ensures that its products meet market requirements by obtaining ISO 13485 certification.

ISO 13485 certification serves as an entry point, and its acquisition signifies that the Aplus factory has established a leading and reliable quality management system, further ensuring the safety and consistency of its products. By producing economically viable products, the Aplus factory allows GaleMed to better adapt to the dynamic changes in the Chinese market, address the tightening policies of China’s healthcare insurance system and centralized procurement requirements, and respond swiftly to the diverse needs and services of various equipment manufacturers.

Sunny He pointed out that the Aplus factory benefits from its prime location, making it possible to rapidly capture more market share with high-quality, cost-effective products. Additionally, by combining clinical expertise with its soft and hard strengths, we are actively striving to drive significant growth in GaleMed's overall revenue.

Looking ahead, Thomas Willemsen, CEO of GaleMed, emphasized that the Aplus factory is not just a strategic hub for GaleMed's expansion in the Chinese market; it also plans to use China as a starting point to gradually expand into the Asia-Pacific region and eventually to the global market through the factory’s production capacity and quality system.

In the context of an aging society and the rising prevalence of chronic diseases, the demand for respiratory care is increasing. GaleMed, through its world-class quality, technology, and innovation, is striving for greater growth in the global medical device industry while continuing to provide high-quality and reliable medical products and services to customers worldwide.